Skip to content
ChickenStockChickenStock
ResearchCSTL
Castle Biosciences logo

Castle Biosciences (CSTL) stock

NASDAQ

$32.93+0.55%(+0.18)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-44.39x

Net loss — not comparable

P/B

2.14x

P/S

2.70x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 24.1% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

40 SEC filings
  • Juvenal Tobin WChief Commercial Officer · Nov 11, 2026Open-market sale6,023 shares · $211K
    Avg. price $35.057832,737 shares held after
    Show 2 price lots
    • 3,195 shares × $35.07$112K
    • 2,828 shares × $35.044$99K
  • Juvenal Tobin WChief Commercial Officer · Nov 11, 2026Option exercise3,195 shares · $94K
    Avg. price $29.535,932 shares held after
  • Juvenal Tobin WChief Commercial Officer · Nov 9, 2026Open-market sale3,288 shares · $107K
    Avg. price $32.6735,565 shares held after
  • MAETZOLD DEREK JPres. & Chief Exec. Officer · Nov 2, 2026Open-market sale14,496 shares · $523K
    Avg. price $36.1017
    Show 6 price lots
    • 7,555 shares × $36.005$272K
    • 2,816 shares × $36.005$101K
    • 2,393 shares × $36.005$86K
    • 1,025 shares × $36.814$38K
    • 382 shares × $36.814$14K
    • 325 shares × $36.814$12K
  • Juvenal Tobin WChief Commercial Officer · Oct 28, 2026Open-market sale6,578 shares · $240K
    Avg. price $36.4231
    Show 2 price lots
    • 5,341 shares × $36.619$196K
    • 1,237 shares × $35.577$44K
  • Juvenal Tobin WChief Commercial Officer · Oct 26, 2026Open-market sale3,288 shares · $109K
    Avg. price $33.0845,431 shares held after
  • MAETZOLD DEREK JPres. & Chief Exec. Officer · Oct 19, 2026Open-market sale14,496 shares · $463K
    Avg. price $31.91
    Show 3 price lots
    • 8,580 shares × $31.91$274K
    • 3,198 shares × $31.91$102K
    • 2,718 shares × $31.91$87K
  • Juvenal Tobin WChief Commercial Officer · Oct 12, 2026Open-market sale3,288 shares · $111K
    Avg. price $33.6448,719 shares held after
  • MAETZOLD DEREK JPres. & Chief Exec. Officer · Oct 5, 2026Open-market sale14,496 shares · $516K
    Avg. price $35.566
    Show 3 price lots
    • 8,580 shares × $35.566$305K
    • 3,198 shares × $35.566$114K
    • 2,718 shares × $35.566$97K
  • MAETZOLD DEREK JPres. & Chief Exec. Officer · Oct 5, 2026Option exercise8,165 shares · $20K
    Avg. price $2.3929,644 shares held after
  • Oelschlager Kristen MChief Operating Officer · Oct 1, 2026Open-market sale4,153 shares · $149K
    Avg. price $35.9542
    Show 2 price lots
    • 2,807 shares × $35.75$100K
    • 1,346 shares × $36.38$49K
  • Oelschlager Kristen MChief Operating Officer · Oct 1, 2026Option exercise4,153 shares · $14K
    Avg. price $3.3817,509 shares held after
  • Juvenal Tobin WChief Commercial Officer · Sep 30, 2026Open-market sale1,034 shares · $35K
    Avg. price $34.252,007 shares held after
  • Juvenal Tobin WChief Commercial Officer · Sep 29, 2026Open-market sale5,543 shares · $197K
    Avg. price $35.49853,041 shares held after
  • MAETZOLD DEREK JPres. & Chief Exec. Officer · Sep 21, 2026Open-market sale14,496 shares · $512K
    Avg. price $35.334
    Show 3 price lots
    • 8,580 shares × $35.334$303K
    • 3,198 shares × $35.334$113K
    • 2,718 shares × $35.334$96K
  • MAETZOLD DEREK JPres. & Chief Exec. Officer · Sep 21, 2026Option exercise8,580 shares · $21K
    Avg. price $2.3930,059 shares held after
  • Juvenal Tobin WChief Commercial Officer · Sep 15, 2026Open-market sale3,294 shares · $116K
    Avg. price $35.14258,584 shares held after
  • Juvenal Tobin WChief Commercial Officer · Sep 14, 2026Open-market sale3,306 shares · $107K
    Avg. price $32.32461,878 shares held after
  • MAETZOLD DEREK JPres. & Chief Exec. Officer · Sep 11, 2026Open-market sale14,518 shares · $465K
    Avg. price $32.0203
    Show 6 price lots
    • 8,361 shares × $32$268K
    • 3,124 shares × $32$100K
    • 2,656 shares × $32$85K
    • 223 shares × $32.78$7K
    • 83 shares × $32.78$3K
    • 71 shares × $32.78$2K
  • MAETZOLD DEREK JPres. & Chief Exec. Officer · Sep 11, 2026Option exercise8,584 shares · $21K
    Avg. price $2.3930,063 shares held after
  • Oelschlager Kristen MChief Operating Officer · Sep 1, 2026Open-market sale3,952 shares · $132K
    Avg. price $33.3613,556 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Castle Biosciences (CSTL) stock information

NASDAQ

Castle Biosciences (CSTL) is listed on NASDAQ. Its market capitalization is about $1B. On trailing-twelve-month earnings the P/E ratio is -44.39, and the P/B ratio is 2.14. Return on equity is -4.8%. These figures are computed in-house from official filings and are reference information only.

Castle Biosciences — frequently asked questions

What is the P/E ratio of Castle Biosciences (CSTL)?
On a trailing-twelve-month basis, CSTL trades at a P/E ratio of -44.39. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Castle Biosciences?
CSTL has a market capitalization of about $1B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.